As a concentration-dependent agent, the bactericidal activity of levofloxacin can be enhanced by introduction of 750 mg o.d. dose. This high-dose regimen produces maximal bactericidal effects, optimal eradication times and reduced selection of resistant bacteria.From a clinical perspective, the more rapid and complete bacterial killing associated with a higher dose of levofloxacin may result in faster resolution of symptoms, thereby allowing an earlier switch from intravenous to oral therapy and earlier hospital discharge. Very importantly, the 750 mg o.d. dose may also allow a shorter course of treatment without compromising clinical efficacy, and may improve patient convenience and adherence to antimicrobial therapy. The higher-dose, shorter course regimen promotes appropriate antimicrobial use by reducing unneeded drug exposure, which further reduces the risk of resistance development and reduces the impact on resident flora. Additionally, short-course therapy may reduce drug costs and the frequency of adverse events.Clinical trials and surveillance studies have shown the 750 mg levofloxacin dose to be well tolerated and even increasing the dose to 1,000 mg did not significantly reduce patient tolerance.